Carmen Criscitiello

Dr. Carmen Criscitiello

New Drugs and Early Drug Development for Innovative Therapies Division, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2020 in Genes
Verified
Journal Article
Open access
PDF file
Nicola FuscoNicola Fusco
Nicola Fusco
Elham SajjadiElham Sajjadi
Elham Sajjadi
Konstantinos VenetisKonstantinos Venetis
Konstantinos Venetis
GGGabriella Gaudioso
Gabriella Gaudioso
GLGianluca Lopez
Gianluca Lopez
Marco InvernizziMarco Invernizzi
Marco Invernizzi
Alterations in the tumor suppressor phosphatase and tensin homolog (PTEN) occur in a substantial proportion of solid tumors. These events drive tumorigenesis and tumor progression. Given its central role as a downregulator of the phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway, PTEN is deeply involved in cell growth, proliferation, and survival. This gene is also implicated in the modulation of the DNA damage response and in tumor immune microenvironment modeling. Despite the actionability of PTEN alterations, their role as biomarkers remains controversial in clinical practice. To date, there is still a substantial lack of validated guidelines and/or recommendations for PTEN testing. Here, we provide an update on the current state of knowledge on biologic and genetic alterations of PTEN across the most frequent solid tumors, as well as on their actual and/or possible clinical applications. We focus on possible tailored schemes for cancer patients’ clinical management, including risk assessment, diagnosis, prognostication, and treatment.


1 October 2017 in The Breast
Verified
Journal Article
Closed access
CSCinzia Solinas
Cinzia Solinas
LCLuisa Carbognin
Luisa Carbognin
PSPushpamali De Silva
Pushpamali De Silva
CCCarmen Criscitiello
Carmen Criscitiello
Matteo LambertiniMatteo Lambertini
Matteo Lambertini

3 July 2020 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
CCCarmen Criscitiello
Carmen Criscitiello
AVA. Vingiani
A. Vingiani
PMPatrick Maisonneuve
Patrick Maisonneuve
GVG. Viale
G. Viale
GCGiuseppe Curigliano
Giuseppe Curigliano

29 March 2020 in Cancers
Verified
Journal Article
Open access
PDF file
ADAnna Diana
Anna Diana
FCfrancesca carlino
francesca carlino
EFElisena Franzese
Elisena Franzese
OOOlga Oikonomidou
Olga Oikonomidou
CCCarmen Criscitiello
Carmen Criscitiello
MOMichele Orditura
Michele Orditura
Triple negative breast cancers (TNBCs) are characterized by worse prognosis, higher propensity to earlier metastases, and shorter survival after recurrence compared with other breast cancer subtypes. Anthracycline- and taxane-based chemotherapy is still the mainstay of treatment in early stages, although several escalation approaches have been evaluated to improve survival outcomes. The addition of platinum salts to standard neoadjuvant chemotherapy (NACT) remains controversial due to the lack of clear survival advantage, and the use of adjuvant capecitabine represents a valid treatment option in TNBC patients with residual disease after NACT. Recently, several clinical trials showed promising results through the use of poly ADP-ribose polymerase (PARP) inhibitors and by incorporating immunotherapy with chemotherapy, enriching treatment options beyond conventional cytotoxic agents. In this review, we provided an overview on the current standard of care and a comprehensive update of the recent advances in the management of early stage TNBC and focused on the latest emerging biomarkers and their clinical application to select the best therapeutic strategy in this hard-to-treat population.

17 September 2014 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
PLPhilip Lammers
Philip Lammers
CCCarmen Criscitiello
Carmen Criscitiello
GCGiuseppe Curigliano
Giuseppe Curigliano
IJIra Jacobs
Ira Jacobs
Trastuzumab in combination with chemotherapy has become a standard of care for patients with HER2+ breast cancer. The cost of therapy, however, can limit patient access to trastuzumab in areas with limited financial resources for treatment reimbursement. This study examined access to trastuzumab and identified potential barriers to its use in the United States, Mexico, Turkey, Russia and Brazil via physician survey. The study also investigated if the availability of a biosimilar to trastuzumab would improve access to and use of HER2 monoclonal antibody therapy. Across all countries, a subset of oncologists reported barriers to the use of trastuzumab in a neoadjuvant, adjuvant or metastatic setting. Common barriers to the use of trastuzumab included issues related to insurance coverage, drug availability and cost to the patient. Overall, nearly half of oncologists reported that they would increase the use of HER2 monoclonal antibody therapy across all treatment settings if a lower cost biosimilar to trastuzumab were available. We conclude that the introduction of a biosimilar to trastuzumab may alleviate cost-related barriers to treatment and could increase patient access to HER2-directed therapy in all countries examined.